{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122770","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.146067+00:00","generated_at":"2026-05-30T03:36:58.782145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Q32 Bio Q3 net loss $17.6M ($1.46/sh); cash $89.1M; bempikibart Phase 2 AD and AA topline due Dec 2024","bullets":["Net loss $17.6M vs $14.0M YoY; R&D expense $14.3M (+$6.8M) on clinical costs and $4M milestone to Bristol-Myers Squibb.","Cash $89.1M expected to fund operations into mid-2026 through four Phase 2 milestones.","Bempikibart SIGNAL-AD trial enrolled 121 patients; topline results in AD and AA both expected December 2024.","ADX-097 Phase 2 renal basket enrollment ongoing; initial open-label data 1H’25, topline 2H’25; AAV trial to start 1H’25.","Positive Phase 1 ADX-097 data presented at ASN Kidney Week 2024 supporting Phase 2 dose."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122770","json":"https://secwatch.observer/filing/0000950170-24-122770.json","markdown":"https://secwatch.observer/filing/0000950170-24-122770.md","text":"https://secwatch.observer/filing/0000950170-24-122770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/0000950170-24-122770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024122770/qttb-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:58.782145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}